Skip to main content
ATRAptarGroup, Inc.Sell4.8·$125.15

AptarGroup (ATR) Q2 2026 earnings — TrendMatrix coverage

BEAT+4.8% vs estimateEPS $1.42 vs $1.35 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Adjusted EPS
$1.42
Estimate
$1.35
Surprise
+4.8%
Score at report (before → after)
5.55.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

AptarGroup (ATR) beat the $1.35 estimate with adjusted EPS of $1.42 — a clear 4.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.5/10) to Hold at 5.6/10 after the report.

Current read · as of 2026-09-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates ATR Sell at 4.8/10.

4 of the last 4 quarters beat the estimate; this quarter's +4.8% surprise compares with a +3.3% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Concentration risk — Supplier: single-source resins and rubber components
  • V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
  • Weak overall score: 4.8/10

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$125.15
Price target
$148.02
Stop
$120.43
Upside to target
+18.3%
Reward-to-risk
3.7:1

At 22.3× trailing and 19.9× forward earnings, consensus estimates imply little change in earnings power.

Model outputs from TrendMatrix’s engine as of 2026-09-23 — shown for context, not personalized investment advice.

Healthcare context

ATR at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Instruments & Supplies
Market cap
$7.98B
P/E (fwd)
19.9
P/E (ttm)
22.3
52-week range
$103.23$146.91
Off 52-week high
14.8%
RSI (14)
34
Volume vs avg
0.30×
Score today
4.8/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ATR Earnings Q2 2026 earnings